Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Dow
Boehringer Ingelheim
Baxter
AstraZeneca
Moodys
Mallinckrodt

Last Updated: May 24, 2022

YASMIN Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Yasmin, and when can generic versions of Yasmin launch?

Yasmin is a drug marketed by Bayer Hlthcare and is included in one NDA.

The generic ingredient in YASMIN is drospirenone; ethinyl estradiol. There are eleven drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the drospirenone; ethinyl estradiol profile page.

Paragraph IV (Patent) Challenges for YASMIN
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
YASMIN Tablets drospirenone; ethinyl estradiol 3 mg/0.03 mg 021098 1 2005-01-07

US Patents and Regulatory Information for YASMIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bayer Hlthcare YASMIN drospirenone; ethinyl estradiol TABLET;ORAL-28 021098-001 May 11, 2001 AB RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for YASMIN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bayer Hlthcare YASMIN drospirenone; ethinyl estradiol TABLET;ORAL-28 021098-001 May 11, 2001 See Plans and Pricing See Plans and Pricing
Bayer Hlthcare YASMIN drospirenone; ethinyl estradiol TABLET;ORAL-28 021098-001 May 11, 2001 See Plans and Pricing See Plans and Pricing
Bayer Hlthcare YASMIN drospirenone; ethinyl estradiol TABLET;ORAL-28 021098-001 May 11, 2001 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for YASMIN

See the table below for patents covering YASMIN around the world.

Country Patent Number Title Estimated Expiration
Eurasian Patent Organization 001947 СПОСОБ ПОЛУЧЕНИЯ ДРОСПИРЕНОНА (6b,7b;15b,16b-ДИМЕТИЛЕН-3-ОКСО-17a-ПРЕГН-4-ЕН-21,17-КАРБОЛАКТОНА, DRSP) И 6b,7b;15b,16b-ДИМЕТИЛЕН-5b-ГИДРОКСИ-3-ОКСО-17a-АНДРОСТАН-21,17-КАРБОЛАКТОН (ZK 90965) В КАЧЕСТВЕ ПРОМЕЖУТОЧНОГО ПРОДУКТА (PROCESS FOR PRODUCING DROSPIRENONE (6beta, 7beta, 15beta, 16beta-DIMETHYLENE-3-OXO-17alpha-PREGN-4-EN-21,17-CARBOLACTONE, DRSP) AND 6beta, 7beta, 15beta, 16beta-DIMETHYLENE-5beta-3-OXO-17alpha-ANDROSTANE-21,17-CARBOLACTONE (ZK 90965) AS INTERMEDIATES) See Plans and Pricing
World Intellectual Property Organization (WIPO) 9806738 See Plans and Pricing
Spain 2438941 See Plans and Pricing
Israel 148339 See Plans and Pricing
Australia 6716700 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for YASMIN

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1214076 C01214076/01 Switzerland See Plans and Pricing PRODUCT NAME: DROSPIRENONE + ETHINYLESTRADIOL; REGISTRATION NUMBER/DATE: SWISSMEDIC 57946 13.06.2008
0398460 04C0022 France See Plans and Pricing PRODUCT NAME: ESTRADIOL ANHYDRE DROSPIRENONE; REGISTRATION NO/DATE IN FRANCE: NL 28661 DU 20040316; REGISTRATION NO/DATE AT EEC: RVG 27505 DU 20021211
0918791 PA2006009 Lithuania See Plans and Pricing PRODUCT NAME: DROSPIRENONUM; NAT. REGISTRATION NO/DATE: LT/1/06/0520/001, 2006 07 10 LT/1/06/0520/002, 2006 07 10 LT/1/06/0520/003, 2006 07 10 LT/1/06/0520/004 20060710; FIRST REGISTRATION: RVG 31781 20050804
1214076 49/2008 Austria See Plans and Pricing PRODUCT NAME: WIRKSTOFFKOMBINATION VON ETHINYLESTRADIOL UND DROSPIRENON; REGISTRATION NO/DATE: 1-27586 20080612
0398460 C300221 Netherlands See Plans and Pricing PRODUCT NAME: DROSPIRENON EN ETHINYLESTRADIOL; REGISTRATION NO/DATE: RVG 23827 20000307
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Boehringer Ingelheim
Harvard Business School
Johnson and Johnson
Dow
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.